[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100577443":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":26,"locations":32,"responsibleParty":53,"collaborators":25,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":25,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":25,"studyType":68,"phases":69,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":35,"whyStopped":25,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"West China Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"low dose","EXPERIMENTAL","1mg\u002Fkg\u002Fd",[13],"Drug: propranolol",{"label":15,"type":16,"description":17,"interventionNames":18},"high dose","ACTIVE_COMPARATOR","2mg\u002Fkg\u002Fd",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","propranolol","different dose",[15,9],null,[27],{"name":28,"role":29,"phone":30,"phoneExt":25,"email":31},"Yi Ji","CONTACT","+862885423453","jijiyuanyuan@163.com",[33],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"West China Hospital of Sichuan University","RECRUITING","Chengdu","Sichuan","610041","China","CN",{"type":42,"coordinates":43},"Point",[44,45],104.06667,30.66667,{"lat":45,"lon":44},[48,49,50],{"name":28,"role":29,"phone":30,"phoneExt":25,"email":31},{"name":25,"role":29,"phone":25,"phoneExt":25,"email":31},{"name":51,"role":52,"phone":25,"phoneExt":25,"email":25},"Yi Ji, Doctor","PRINCIPAL_INVESTIGATOR",{"type":52,"investigatorFullName":28,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Doctor","100577443","phase-2-efficacy-and-safety-of-different-initial-doses-of-oral-propranolol-in-the-treatment-of-ulcerated-infantile-hemangioma-100577443",false,"NCT06798363","Efficacy and Safety of Different Initial Doses of Oral Propranolol in the Treatment of Ulcerated Infantile Hemangioma","Efficacy and Safety of Different Initial Doses of Oral Propranolol in the Treatment of Ulcerated Infantile Hemangioma： a Prospective Study","Inclusion Criteria:\n\n1. all patients with ulcer IH;\n2. children with ulcer IH treated with propranolol.\n\nExclusion Criteria:\n\n1\\) children with ulcer IH who received other therapeutic interventions were excluded; 2) Children whose families refused to participate in the study; 3) patients with contraindications to oral propranolol, such as allergy to propranolol, severe bradycardia and bronchial asthma; 4) children lost to follow-up during oral propranolol treatment; 5) children unable to oral propranolol or continue to oral propranolol due to other reasons.\n\n\\-","ALL","1 Month","4 Years",{"count":66,"type":67},24,"ESTIMATED","INTERVENTIONAL",[70,71],"PHASE2","PHASE3","The main objective of this study was to determine the efficacy of different doses of propranolol in the treatment of ulcerattion infantile hemangioma (IH).",[74],"Infantile Hemangioma",[76],"Infantile hemangioma, ulcer, propranolol","2026-07-19",{"date":79,"type":80},"2026-07-21","ACTUAL",{"date":82,"type":80},"2025-05-02",{"date":84,"type":67},"2026-08-01",{"name":5,"class":6},1]